MOR202

DRUG3 trials

Sponsors

HI-Bio, A Biogen Company, Mario Negri Institute for Pharmacological Research

Conditions

GlomerulonephritisGlomerulonephritis, MembranousMembranous NephropathyantiPLA2R Positive

Phase 1

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

CompletedNCT04145440

HI-Bio, A Biogen CompanyantiPLA2R Positive, Glomerulonephritis, Membranous

Start: 2019-10-15End: 2022-08-02Updated: 2025-02-24

Phase 2

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

CompletedNCT04733040

HI-Bio, A Biogen CompanyantiPLA2R Positive, Glomerulonephritis, Membranous Nephropathy

Start: 2021-01-20End: 2023-12-14Updated: 2025-02-07

MOR202 for Refractory MN

CompletedNCT04893096

Mario Negri Institute for Pharmacological ResearchMembranous Nephropathy

Start: 2021-10-22End: 2025-02-21Updated: 2026-07-13

Related Papers

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.

2024-06-2015 citations

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Trials2022-04-0823 citations